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Abstract
Background: Selecting high-risk participants for dementia prevention trials based on a modifiable dementia risk
score may be advantageous, as it increases the opportunity for intervention. We studied whether a multi-domain
intervention can prevent all-cause dementia and cognitive decline in older people across three different levels of a
modifiable dementia risk score.
Methods: Prevention of Dementia by Intensive Vascular Care (preDIVA) is a randomised controlled trial studying
the effect of multi-domain vascular care during 6–8 years on incident all-cause dementia in community-dwelling
people aged 70–78 years. For this post hoc analysis, we stratified preDIVA participants in tertiles based on their
baseline LIfestyle for BRAin Health (LIBRA) index, a modifiable dementia risk score. With Cox proportional hazards
regression, the intervention effect on dementia was assessed. The effect on cognition was measured every 2 years
with the Mini-Mental State Examination and Visual Association Test.
Results: Dementia developed in 220 of 3274 (6.7%) participants. In participants with a low, intermediate and high
LIBRA index, the hazard ratio (HR) of the intervention on incident dementia was respectively 0.71 (95% CI 0.45–1.12),
1.06 (95% CI 0.66–1.69) and 1.02 (95% CI 0.64–1.62). Also, when adding the non-modifiable risk factors age,
education and sex to the index, results were comparable (respectively HR 0.88, 95% CI 0.54–1.43; HR 0.91, 95% CI 0.
57–1.47; HR 0.92, 95% CI 0.59–1.41). There was no statistically significant intervention effect on cognition during
follow-up across the LIBRA groups.
Conclusions: In the preDIVA study population aged 70–78 years, the LIBRA modifiable dementia risk score did not
identify a (high-)risk group in whom the multi-domain intervention was effective in preventing dementia or
cognitive decline.
Trial registration: International Standard Randomised Controlled Trial Number registry, ISRCTN29711771. Registered
on 14 February 2006.
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Background
The number of dementia cases worldwide is antici-
pated to double over the coming two decades [1, 2].
Up to a third of Alzheimer’s disease cases may be at-
tributable to potentially modifiable risk factors, in-
cluding several vascular risk factors such as diabetes
mellitus, midlife hypertension and physical inactivity
[3]. This offers a window of opportunity for preven-
tion strategies. However, selection of the optimal tar-
get population when designing a randomised
controlled trial (RCT) to prevent dementia remains a
challenge [4]. Results from recent RCTs suggest that
interventions may be most effective in those individ-
uals at increased risk of dementia based on the pres-
ence of one or more dementia risk factors [5–7]. In
such an at-risk population the potential to improve
modifiable risk factors such as hypertension and phys-
ical inactivity, and thereby prevent dementia, is
higher. In addition, the higher dementia incidence
rates in high-risk populations increase the study
power, decreasing the total number of participants re-
quired to demonstrate a treatment effect.
A dementia risk score could be a useful tool to re-
cruit a high-risk population for prevention trials.
Most risk scores that have been developed are, how-
ever, heavily dependent on non-modifiable risk fac-
tors such as age, sex and education [8]. The
LIfestyle for BRAin Health (LIBRA) index is the
first, and so far only, validated dementia risk score
predominantly supported by modifiable health and
lifestyle factors [9]. It consists of the following 12
risk and protective factors: depression, hypertension,
obesity, smoking, hypercholesterolemia, diabetes,
renal dysfunction, physical inactivity, coronary heart
disease, low/moderate alcohol use, cognitive activity
and adherence to the Mediterranean diet. As the
index reflects an individual’s potential for dementia
prevention, it may identify those most responsive to
an intervention.
Prevention of Dementia by Intensive Vascular Care
(preDIVA) is a cluster RCT evaluating the effect of
6–8 years of nurse-led intensive vascular care on inci-
dent dementia in community-dwelling older people
aged 70–78 years [5]. Overall, no preventive effect of
the intervention was found. The intervention seemed
more beneficial in a subgroup of individuals with un-
treated hypertension who adhered to the intervention.
As the preDIVA intervention targets several vascular
risk factors, our hypothesis was that a risk score cap-
turing several modifiable risk factors may function
even better at selecting those individuals responsive
to the intervention.
Hence, our aim was to study whether a multi-domain
intervention can prevent all-cause dementia and
cognitive decline in older people across three different
levels of a modifiable dementia risk score.
Methods
The current study is a post hoc analysis in the preDIVA
trial, which was published previously [5]. In short, the
intervention comprised 4-monthly visits to a practice
nurse who gave individually tailored lifestyle advice on
smoking, diet, physical activity, weight and blood pressure
(BP). If indicated, pharmacological treatment was started
or optimised according to the prevailing guidelines on car-
diovascular risk management [10]. The control condition
was standard care. All community-dwelling older people
aged 70–78 years registered at participating Dutch general
practices were invited to participate. The only exclusion
criteria were a diagnosis of dementia and/or any condition
likely to hinder long-term follow-up (such as terminal ill-
ness or alcoholism). The trial is registered at the Inter-
national Standard Randomised Controlled Trial Number
registry (ISRCTN29711771).
LIBRA index
The LIBRA index has been designed based on a sys-
tematic review and Delphi consensus, and has been
validated in several cohorts, including a cohort aged
70–79 years [9, 11, 12]. In preDIVA, 10 out of 12
LIBRA factors were measured at baseline (Table 1).
Similar to one of the previously mentioned validation
studies [11], there was no information on cognitive
activity or adherence to the Mediterranean diet. Data
on medical history, medication use, history of smok-
ing and alcohol use were self-reported and
cross-referenced with the electronic medical record of
the general practitioner. BP, weight and height (to cal-
culate the body mass index (BMI)) were measured
using standard protocols. A blood sample was drawn
to measure cholesterol and creatinine levels. The
15-item Geriatric Depression Scale was used to meas-
ure depressive symptoms and the LASA Physical Ac-
tivity Questionnaire to measure physical activity [13,
14]. The measures corresponding to the 10 LIBRA
items (Table 1) were aligned to the previously pub-
lished validation studies [9, 11]. Each item was
assigned the appropriate score (Table 1) and the sum
of these items formed the LIBRA index (with a max-
imum potential range of − 1.0 to + 12.7). Only partici-
pants with all 10 items available to calculate the
LIBRA index were included in the analysis. For a sec-
ondary analysis, the LIBRA index was extended with
the non-modifiable risk factors age, sex and education
(Table 1), in order to make it more comparable to
other available dementia risk indices [15]. This was
also done in the previously published studies on the
LIBRA index [9, 11].
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Primary and secondary outcomes
The primary outcome was all-cause dementia, according
to the Diagnostic and Statistical Manual of Mental Dis-
orders IV [16]. An independent outcome adjudication
committee validated all dementia diagnoses, including a
1-year follow-up period in incident cases to assure there
were no false positive diagnoses. Cognition was the sec-
ondary outcome measure, which was measured every 2
years with the Mini-Mental State Examination (MMSE)
and the Visual Association Test (VAT) [17, 18].
Participants attending at least one follow-up visit were
included in the analyses on cognition.
Statistical analysis
We first assessed the association between the LIBRA
index in the preDIVA population and incident dementia
with Cox proportional hazards regression. We then di-
vided the study population into participants with a low,
intermediate and high LIBRA index based on tertiles of
the index [11]. In each group, the crude effect of the
intervention on all-cause dementia was assessed with
Cox proportional hazards regression (model 1). The
years from randomisation to dementia diagnosis or cen-
soring date were used as the timescale. To assess
whether the LIBRA index is more useful as a selection
tool when containing both modifiable and major
non-modifiable risk factors, we repeated our analysis
with the LIBRA index expanded with education (model
2) and additionally with age and sex (model 3) [11]. As
history of coronary heart disease is not modifiable, we
removed it from the LIBRA index in a sensitivity ana-
lysis (model 4). Our primary analysis was crude and in a
secondary analysis we adjusted for baseline imbalances
between the intervention and control groups. We also
assessed the effect of adjusting for education, as this is
an important risk factor for dementia and is associated
with many of the risk/protective factors included in the
LIBRA index [3]. The proportional hazards assumption
was tested using Schoenfeld residuals and was assessed
graphically [19].
Because of the cluster-randomised design we addition-
ally performed a multi-level analysis to account for clus-
tering within general practices and health care centres.
To account for competing risk of death, we assessed the
intervention effect on mortality in the LIBRA groups,
and, when appropriate, performed a competing risk ana-
lysis according to the cause-specific hazard method [20].
We added a per-protocol analysis to assess whether the
results were influenced by adherence to the intervention
or control condition. In the per-protocol analysis, we ex-
cluded intervention participants who had on average less
than two visits per year and inadvertent crossover con-
trol participants who had on average more than two
visits per year. As the LIBRA index is more sensitive in a
younger cohort [11], we performed a pre-defined sub-
group analysis on age (dichotomised at the median). In
the primary preDIVA analyses, the intervention seemed
to be effective in those individuals with untreated hyper-
tension who adhered to the intervention. However, the
LIBRA definition of hypertension is rather crude (di-
chotomously defined as systolic BP ≥ 140 mmHg, dia-
stolic BP ≥ 90 mmHg and/or use of antihypertensive
medication). Therefore, we added subgroup analyses on
World Health Organisation hypertension grades (i.e.
Table 1 Definition of risk/protective factors in the LIBRA index
and corresponding scores [11]
Definition Score
Modifiable risk factors
Depression Score≥ 5 on the
15-item Geriatric Depression Scale
+ 2.1
Hypertension SBP ≥ 140 mmHg,
DBP ≥ 90 mmHg
and/or use of
antihypertensive medication
+ 1.6
Obesity BMI ≥ 30 + 1.6
Smoking Current smoker + 1.5
Hypercholesterolemia Total
cholesterol ≥
6.2 mmol/L or use of
cholesterol-lowering
medication
+ 1.4
Diabetes Diabetes mellitusa + 1.3
Renal dysfunction Estimated glomerular filtration
rate < 60 ml/min/1.73 m2 b
+ 1.1
Physical inactivity Not fulfilling World Health
Organisation criteria for
physical activity as measured
with LASA Physical Activity
Questionnairec
+ 1.1
Coronary heart
disease
Cardiovascular disease (defined as
myocardial infarction, angina or
peripheral arterial disease)a
+ 1.0
Low/moderate
alcohol use
Alcohol use 1–14 units per week
for males and 1–7 for females [21]
−1.0
Non-modifiable risk factors
Age Males: 70–74 years + 5.2
Male: 75–78 years + 6.8
Females: 70–74 years + 6.2
Female: 75–78 years + 9.2
Education High: ≥ 13 years 0
Medium: 7–13 years + 1.4
Low: ≤ 7 years + 2.7
LIBRA LIfestyle for BRAin Health, SBP systolic blood pressure, DBP diastolic
blood pressure, BMI body mass index
aData self-reported and cross-checked with electronic health records
bEstimated glomerular filtration rate calculated with the creatinine-based
Chronic Kidney Disease–Epidemiology Collaboration equation [27]
cWorld Health Organisation criteria for physical activity defined as ≥ 150 min/
week moderate intensity or ≥ 75 min/week vigorous intensity or an
equivalent combination
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normotension, systolic BP < 140 mmHg and/or diastolic
BP < 90 mmHg; grade I hypertension, systolic BP 140–
160 mmHg and/or diastolic BP 90–100 mmHg; grade II
or III hypertension, systolic BP ≥ 160 mmHg and/or dia-
stolic BP ≥ 100 mmHg) and use of antihypertensive
medication [21]. In the Netherlands, people with a his-
tory of cardiovascular disease (CVD) and diabetes visit a
practice nurse as part of standard care, potentially dilut-
ing an intervention effect [22]. We therefore added ana-
lyses in subgroups based on history of CVD and type 2
diabetes. To assess whether the intervention led to an
improvement of cardiovascular risk factors, as a proxy
for treatment effect, we compared decline in systolic BP,
BMI and total cholesterol between baseline and the last
available follow-up visit, across the three LIBRA groups.
To assess whether individual changes in cognition vary
over time between treatment groups, we used a multi-
level growth model stratified for participants with a low,
intermediate and high LIBRA index [23]. In this linear
mixed-effect model each participant and time in years
were considered random effects and a time × random-
isation interaction variable was included. Since absolute
values of the MMSE and VAT, or logarithmic transform-
ation of these values, were not normally distributed,
change in MMSE/VAT since baseline, which was nor-
mally distributed, was used as an outcome variable in
the model. We performed our analyses in R studio ver-
sion 3.2 using the survival and nlme packages [24].
Results
Of the 3526 preDIVA participants at baseline, 3339
(94.7%) had all 10 LIBRA items available at baseline and
could be included in the analyses (Additional file 1: Fig-
ure S1). The median LIBRA score at baseline was 3.1.
Participants with the highest LIBRA index were slightly
older (low 74.2 years, intermediate 74.3 years, high
74.5 years; p < 0.01) and more often had a low education
level (low 19.2%, intermediate 22.1%, high 29.9%; p <
0.01; Table 2). Systolic BP was highest in the intermedi-
ate LIBRA group (low 151.5 mmHg, intermediate
157.5 mmHg, high 156.7 mmHg; p < 0.01). The baseline
characteristics of the intervention and control groups
within each LIBRA group were well balanced, except for
small differences in total cholesterol (respectively, 5.3 vs
5.5 mmol/L; p = 0.03) in the intermediate LIBRA group
and mean systolic BP (157.9 vs 155.3 mmHg; p = 0.04)
and sex (37.3% vs 44.2%; p = 0.02) in the high LIBRA
group (Additional file 1: Table S1).
All-cause dementia was diagnosed in 220 (6.7%) par-
ticipants; 76 of 1091 participants (7.0%) participants with
a low LIBRA index, 71 of 1081 (6.6%) with an intermedi-
ate LIBRA index and 73 of 1102 participants (6.6%) with
a high LIBRA index. The LIBRA index (model 1) was
not associated with incident dementia (crude hazard
ratio (HR) 1.02 per point increase in LIBRA index, 95%
confidence interval (CI) 0.96–1.09). Adding education to
the LIBRA index (model 2) did not change these results
(HR 1.06; 95% CI 0.90–1.24). The LIBRA index includ-
ing education, age and sex (model 3) was significantly
associated with incident dementia (HR 1.07, 95% CI
1.02–1.12).
The HR of the effect of intensive vascular care on inci-
dent all-cause dementia was 0.71 (95% CI 0.45–1.12) in
the low, 1.06 (95% CI 0.66–1.69) in the intermediate and
1.02 (95% CI 0.64–1.62) in the high LIBRA groups
(model 1; Fig. 1; Table 3). The interaction between ran-
domisation and LIBRA index divided into tertiles was
not significant. Also, when including age, sex and educa-
tion in (models 2 and 3) or excluding coronary heart dis-
ease from (model 4) the LIBRA index and stratifying our
study population based on this modified LIBRA index,
the intervention was not effective in any of the groups
(Table 3). Adjustment for baseline imbalances or educa-
tion did not significantly influence the results, nor did
accounting for clustering within general practices and
health care centres (Additional file 1: Table S2). The re-
sults were similar in the per-protocol analysis (Add-
itional file 1: Table S2). Mortality risk increased with
increasing LIBRA index, but the intervention effect on
mortality was not significantly different in the LIBRA
groups (Additional file 1: Table S3). In all secondary ana-
lyses, the HR was lowest, albeit non-significant, in par-
ticipants with the lowest LIBRA index (Additional file 1:
Table S2). Subgroup analyses showed a significant inter-
action (p = 0.03) between age and randomisation in the
intermediate LIBRA group with a lower HR in younger
participants aged < 74.3 years (HR 0.55; 95% 0.26–1.17)
compared to older participants (HR 1.65; 95% CI 0.88–
3.09) (Additional file 1: Table S4). We found an inter-
action with diabetes in the high LIBRA group (p = 0.03),
with a lower HR in participants with diabetes (HR 0.61;
95% CI 0.32–1.15) in comparison to those without (HR
1.78; 95% CI 0.87–3.64). We found no other interactions
in the subgroup analyses. Participants with a higher
LIBRA index had on average more decline in systolic BP
(respectively in the low, intermediate and high LIBRA
groups − 2.3, − 5.9 and − 5.8; p < 0.01), less decline in
total cholesterol (− 0.3, − 0.3 and − 0.1; p < 0.01) and
more decline in BMI (− 0.5, − 0.5 and − 0.9; p < 0.01).
The intervention led to a significant decline in systolic
BP in the low (intervention vs control − 3.9 vs − 0.5; p =
0.03) and intermediate (− 7.4 vs − 4.2; p = 0.04) LIBRA
groups, but not in the high LIBRA group (− 7.1 vs − 4.3;
p = 0.09; Additional file 1: Table S5). The intervention
did not significantly reduce cholesterol or BMI in any of
the LIBRA groups (Additional file 1: Table S5).
A total of 2674 participants had at least one valid
MMSE score and 2671 participants at least one valid
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VAT score after baseline and could be included in the
analyses on cognitive decline (Additional file 1: Figure
S1). Participants excluded from these analyses were on
average older, had a higher cardiovascular risk and had a
lower baseline MMSE and VAT (Additional file 1: Table
S6). After 3 years, decline in MMSE did not significantly
differ between the intervention and control groups
among participants with a low (mean difference (MD) −
0.08; 95% CI − 0.28 to 0.13), intermediate (MD 0.07; 95%
CI − 0.14 to 0.27) or high (MD − 0.06; 95% CI − 0.30 to
0.18; Fig. 2a, Additional file 1: Table S7) LIBRA index.
Decline in VAT also did not differ between treatment
groups in the low (MD 0.03; 95% CI − 0.09 to 0.14),
intermediate (MD − 0.04; 95% CI − 0.16 to 0.08) or high
(MD 0.07; 95% CI − 0.05 to 0.19; Fig. 2b, Additional
file 1: Table S7) LIBRA groups.
Discussion
In the preDIVA study population, aged 70–78 years,
the LIBRA index did not identify a high-risk group in
whom the multi-domain intervention was effective in
preventing dementia or cognitive decline. On the con-
trary, there was a trend for a preventive effect in the
subgroup with a low LIBRA index. Results were
Table 2 Baseline characteristics by LIBRA group
Low LIBRA index Intermediate LIBRA index High LIBRA index p value
Total number of participants 1091 1081 1102
Range in LIBRA index −1.0 to 2.6 2.6 to 4.2 4.2 to 11.6
Demographics
Age (years) 74.2 (2.5) 74.3 (2.5) 74.5 (2.5) < 0.01
Sex (male) 528 (48.4%) 519 (48.0%) 445 (40.4%) < 0.01
Education < 0.01
Low (< 7 years) 209 (19.2%) 239 (22.1%) 330 (29.9%)
Medium (7–12 years) 695 (63.7%) 671 (62.1%) 660 (59.9%)
High (> 12 years) 179 (16.4%) 161 (14.9%) 101 (9.2%)
Race (white) 1057 (96.9%) 1042 (96.4%) 1054 (95.6%) < 0.01
Medical history
CVD (excluding stroke or TIA) 66 (6.0%) 372 (34.4%) 526 (47.7%) < 0.01
Stroke or TIA 60 (5.5%) 95 (8.8%) 169 (15.3%) < 0.01
Cardiovascular risk factors
Systolic BP (mmHg) 151.5 (22.0) 157.5 (20.8) 156.7 (20.6) < 0.01
Diastolic BP (mmHg) 81.0 (10.9) 82.0 (10.9) 81.3 (11.0) 0.09
Total cholesterol (mmol/L) 5.4 (0.9) 5.4 (1.1) 4.9 (1.2) < 0.01
LDL cholesterol (mmol/L) 3.3 (0.8) 3.2 (1.0) 2.8 (1.0) < 0.01
Body mass index (kg/m2) 25.9 (3.1) 26.7 (3.6) 29.6 (4.6) < 0.01
Type 2 diabetes 30 (2.7%) 103 (9.5%) 460 (41.7%) < 0.01
Smoking (currently) 46 (4.2%) 113 (10.5%) 265 (24.0%) < 0.01
Alcohol use (units/week) 3 (0–7) 4 (0–14) 0 (0–10) < 0.01
Physically active (WHO) 1065 (97.6%) 990 (91.6%) 784 (71.1%) < 0.01
Creatinine (μmol/L) 77 (68–88) 80 (68–93) 82 (71–97) < 0.01
Medication use
Antihypertensive medication 332 (30.4%) 631 (58.4%) 838 (76.0%) < 0.01
Cholesterol-lowering medication 77 (7.1%) 370 (34.2%) 664 (60.3%) < 0.01
Disability and neuropsychiatric assessment
Mini-Mental State Examination 29 (28–30) 28,5 (27–29) 28 (27–29) < 0.01
Visual Association Test 6 (5, 6) 6 (5, 6) 6 (5, 6) 0.05
Geriatric Depression Scale 1 (0–1) 1 (0–2) 2 (0–4) < 0.01
Data presented as number (percentage), mean (standard deviation) or median (interquartile range)
LIBRA LIfestyle for BRAin Health, CVD indicates cardiovascular disease TIA transient ischemic attack, BP blood pressure, LDL low-density lipoprotein, WHO World
Health Organisation
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comparable when including non-modifiable risk fac-
tors in the LIBRA index.
The concept of selecting people at increased risk of
dementia for preventive interventions to magnify the
intervention effect is widely supported among experts in
the field and has been incorporated in the design of re-
cent multi-domain prevention trials [6, 7]. Our results
do not support this strategy, and are even in contrast
with this concept, at least in later life, suggesting a more
favourable effect of the intervention in those with a low
Fig. 1 Cumulative incidence curves of risk of dementia comparing intervention and control groups in participants with low, intermediate and
high LIBRA index. Line indicates incidence, shaded area indicates 95% CI. Numbers of participants at risk at 6-year follow-up were 791 in low (408
intervention; 383 control), 756 in intermediate (400 intervention; 356 control) and 738 in high (406 intervention, 332 control) LIBRA groups. LIBRA
LIfestyle for BRAin Health
Table 3 Intervention effect on incident all-cause dementia across the models, by LIBRA group
LIBRA group Intervention, n/N
(%)
Control, n/N
(%)
Hazard ratio (95%
CI)
p value for
interaction
Model 1: LIBRA index Low 33/567 (5.8%) 43/524 (8.2%) 0.71 (0.45–1.12) Ref.
Intermediate 39/576 (6.8%) 32/505 (6.3%) 1.06 (0.66–1.69) 0.23
High 41/606 (6.8%) 32/496 (6.5%) 1.02 (0.64–1.62) 0.27
Model 2: LIBRA index including education Low 28/555 (5.0%) 39/498 (7.8%) 0.64 (0.40–1.05) Ref.
Intermediate 38/525 (7.2%) 31/482 (6.4%) 1.11 (0.69–1.79) 0.12
High 46/660 (7.0%) 35/525 (6.7%) 1.03 (0.66–1.59) 0.17
Model 3: LIBRA index including age, sex and
education
Low 32/564 (5.7%) 33/515 (6.4%) 0.88 (0.54–1.43) Ref.
Intermediate 35/568 (6.2%) 34/510 (6.7%) 0.91 (0.57–1.47) 0.94
High 45/608 (7.4%) 38/480 (7.9%) 0.92 (0.59–1.41) 0.92
Model 4: LIBRA index excluding coronary heart
disease
Low 36/559 (6.0%) 45/559 (8.1%) 0.75 (0.48–1.16) Ref.
Intermediate 35/570 (6.1%) 28/477 (5.9%) 1.05 (0.64–1.72) 0.32
High 42/580 (7.2%) 34/489 (7.0%) 1.01 (0.64–1.59) 0.34
LIBRA LIfestyle for BRAin Health, CI confidence interval, Ref. reference category
van Middelaar et al. Alzheimer's Research & Therapy  (2018) 10:62 Page 6 of 10
Fig. 2 Effect of intervention on MMSE (a) and VAT (b) change since baseline in LIBRA groups. Trajectories of change in MMSE and VAT since
baseline comparing control group (red line) to intervention group (blue line) in each LIBRA group, as predicted with multilevel growth model.
Positive value indicates increase in MMSE/VAT since baseline, negative value indicates decrease. LIBRA LIfestyle for BRAin Health, MMSE Mini-
Mental State Examination, VAT Visual Association Test
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LIBRA index. A potential explanation for this is that the
contrast between the intervention and control condi-
tions was too small, partly due to Hawthorne effects and
improvements in the standard care for cardiovascular
risk management during the trial [5]. Although a greater
reduction in systolic BP could be achieved in partici-
pants with a higher LIBRA index, this was the case in
both the intervention and control groups and the differ-
ence between the treatment groups was smallest in the
high LIBRA group. Another potential explanation for
our results is that the LIBRA index does not successfully
classify dementia risk in this older population aged 70–
78 years. Indeed, our analyses did not show an associ-
ation between a high LIBRA index and increased risk of
dementia. Since preDIVA is an RCT, this could poten-
tially (partly) be due to the fact that the dementia risk
was influenced during the trial by the intervention and/
or Hawthorne effects [5]. For example, systolic BP de-
creased by approximately 8 mmHg in the intervention
group and 4 mmHg in the control group, and the de-
cline was steepest in participants with hypertension at
baseline [5]. In one of the LIBRA validation studies, a
higher LIBRA index was associated (at group level) with
an increased risk of dementia in people aged 70–79 years
[11]. The individual predictive accuracy in late life was
poor, however, with a C statistic of 0.50, and seemed to
decrease with increasing age. Investigating the utility of
the LIBRA index as a selection tool for prevention trials
at a younger age (55–70 years) may yield different re-
sults. A third potential explanation is that the factors in
the LIBRA index and in other dementia risk scores are
dichotomous and not designed to precisely quantify the
magnitude of the risk/protective factor or the room for
improvement. For example, the potential for improve-
ment is different for someone with a systolic BP of
125 mmHg on antihypertensive medication compared to
a person with a systolic BP of 155 mmHg without medi-
cation, although both are weighted equally in the LIBRA
index with the dichotomous score for hypertension (in-
cluding both high BP and/or antihypertensive medica-
tion use). In order for a risk estimation tool to be useful
for selection of high-risk populations for dementia pre-
vention trials, the potential for improvement should be
taken into account (e.g. by distinguishing treated or un-
treated hypertension).
Regardless of the LIBRA index performance in high-age
populations, the concept of selecting people at high risk of
dementia may only be appropriate for younger people (i.e.
age < 70 years). In older people at high risk of dementia,
cerebrovascular and neurodegenerative damage may
already be irreversible, while those with a low risk could
still benefit from risk factor improvement in order to
maintain cognitive function. Also, several observational
studies have shown a diminishing or even inverting
association between risk factors and incident dementia in
older people, as for example the J-shaped relation with BP
[25]. Therefore, future trials should perhaps either focus
on people with lowest dementia risk in old age or highest
dementia risk in midlife. This would, however, imply that
substantially larger sample sizes or longer follow-up will
be required, as incidence rates in these groups are lower.
A strength of this analysis is that preDIVA is, up until
now, the only multi-domain prevention trial with dementia
as the primary outcome. The population-based approach
with few exclusion criteria renders preDIVA a suitable
study to test whether the LIBRA index is a promising tool
to select high-risk groups from the general population. A
limitation is the overall neutral result of the preDIVA trial,
perhaps limiting the possibility to detect high-risk groups
who benefit most. However, a significant effect of the inter-
vention was found in the per-protocol analysis among par-
ticipants with untreated hypertension at baseline (HR 0.54,
95% CI 0.32–0.92) [5], while the results of the present ana-
lyses do not show a trend towards improved treatment ef-
fects in higher LIBRA groups. Another limitation is that no
other neuropsychological tests were performed besides the
MMSE and VAT to detect more subtle cognitive changes.
We did not have information on two of the 12 LIBRA
items, including cognitive activity which is the
strongest-weighted item in the LIBRA index [9]. These fac-
tors were, however, already identified as risk factors that
need further validation in the systematic review and Delphi
consensus used to design the LIBRA index, and were also
not included in the validation study among people in late
life (70–79 years) [11, 12]. Furthermore, it may be argued
that cognitive activity at this age is not as much a modifi-
able risk factor but rather an early indicator of developing
cognitive decline and dementia [26].
Conclusions
Within our study population of community-dwelling
people aged 70–78 years, a modifiable dementia risk
score does not identify heterogeneity in the treatment ef-
fect of a multi-domain intervention to prevent dementia
or cognitive decline. This suggests that in older adults a
high LIBRA index may not be a suitable parameter to
select participants for a dementia prevention trial. Spe-
cific characteristics of the preDIVA study, including the
overall neutral effect of the intervention and relatively
high age group, may have contributed to the lack of dis-
criminating capacity of the LIBRA index.
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